Stoke Therapeutics Completes Phase 3 Enrollment for Zorevunersen, Targets Q3 2027 Data Readout
STOK has more than doubled off its 52-week low of $11.19.
Summary
Stoke Therapeutics has completed enrollment of 162 patients in its pivotal Phase 3 EMPEROR study for zorevunersen. This is a critical de-risking milestone for the company, especially given its reported Q1 2026 revenue decline. The completion of enrollment provides a clear path forward for its lead drug candidate. Phase 3 data readout is anticipated in Q3 2027, with a rolling U.S. NDA submission planned to commence in Q1 2027 and conclude in the second half of 2027.
At the time of this announcement, STOK was trading at $32.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $11.19 to $40.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.